Cholangiocarcinoma is the second most common primary liver cancer. Its incidence is low in
the Western world but is rising globally. Surgery, chemotherapy and radiation therapy have …

Summary The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium
(CPTAC) investigates tumors from a proteogenomic perspective, creating rich multi-omics …

Organoid models have the potential to recapitulate the biological and pharmacotypic
features of parental tumors. Nevertheless, integrative pharmaco-proteogenomics analysis …

Objective The diversity of the tumour microenvironment (TME) of intrahepatic
cholangiocarcinoma (iCCA) has not been comprehensively assessed. We aimed to …

Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and
an extremely high mortality rate. Here, we performed whole-exome sequencing, RNA …

Background & Aims The landscape and function of the immune infiltrate of intrahepatic
cholangiocarcinoma (iCCA), a rare, yet aggressive tumor of the biliary tract, remains poorly …

We have developed a deep-scale proteome and phosphoproteome database from 44
representative acute myeloid leukemia (AML) patients from the LAML TCGA dataset and 6 …

Abstract N 6‐Methyladenosine (m6A) is an important RNA modification catalyzed by
methyltransferase‐like 3 (METTL3) and METTL14. m6A homeostasis mediated by the …

Cancer is generally regarded as a localised disease, with the well-established role of the
tumour microenvironment. However, the realm of cancer goes beyond the tumour …

Abstract N6-methyladenosine (m6A) RNA methylation and its associated methyltransferase
like 3 (METTL3) are involved in the development and maintenance of various tumors. The …